Giordano M, Capelli L, Chianese U
Arzneimittelforschung. 1975 Mar;25(3):435-7.
A new nonsteroidal anti-inflammatory agent, 1-(p-chlorobenzyl)-5-methylindole-3-acetic acid monohydrate glucosamide (glucametacine, Teoremac¿), was used in the treatment of a total of 39 patients including 31 cases of rheumatoid arthritis, 3 of ankylosing spondylitis, 1 of psoriatic rheumatism, 1 of chronic chondrocalcinosis and 3 of arthrosis. Teoremac was given for 14 days at a dosage of 420 mg/day. The drug was shown to be more or less active in all the patients except 4. The improvement in the various clinical parameters of rheumatoid arthritis studied was statistically significant. The side effects recorded were headache, which was severe in only 1 case, and "minor" disturbances of the gastro-intestinal tract. A double blind crossover trial was carried out in 15 patients with rheumatoid arthritis to compare the action of Teoremac (420 mg/day for 14 days) with that of indometacin (100 mg/day for 14 days). Under the conditions of the trial, the clinical findings showed Teoremac to be slightly superior to indometacin, but the difference was not significant statistically.
一种新型非甾体抗炎药，1-（对氯苄基）-5-甲基吲哚-3-乙酸一水合葡糖酰胺（葡甲胺，Teoremac®），用于治疗总共39例患者，其中包括类风湿性关节炎31例、强直性脊柱炎3例、银屑病性风湿病1例、慢性软骨钙质沉着症1例和关节病3例。给予Teoremac，剂量为420毫克/天，持续14天。除4例患者外，该药在所有患者中均或多或少有活性。所研究的类风湿性关节炎各项临床参数的改善具有统计学意义。记录到的副作用为头痛，仅1例严重，以及胃肠道“轻微”不适。对15例类风湿性关节炎患者进行了双盲交叉试验，以比较Teoremac（420毫克/天，持续14天）与吲哚美辛（100毫克/天，持续14天）的作用。在试验条件下，临床结果显示Teoremac略优于吲哚美辛，但差异无统计学意义。
